238 related articles for article (PubMed ID: 35573047)
1. Pharmacological interventions enhance virus-free generation of
Kath J; Du W; Pruene A; Braun T; Thommandru B; Turk R; Sturgeon ML; Kurgan GL; Amini L; Stein M; Zittel T; Martini S; Ostendorf L; Wilhelm A; Akyüz L; Rehm A; Höpken UE; Pruß A; Künkele A; Jacobi AM; Volk HD; Schmueck-Henneresse M; Stripecke R; Reinke P; Wagner DL
Mol Ther Methods Clin Dev; 2022 Jun; 25():311-330. PubMed ID: 35573047
[TBL] [Abstract][Full Text] [Related]
2. Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing.
Balke-Want H; Keerthi V; Gkitsas N; Mancini AG; Kurgan GL; Fowler C; Xu P; Liu X; Asano K; Patel S; Fisher CJ; Brown AK; Tunuguntla RH; Patel S; Sotillo E; Mackall CL; Feldman SA
Mol Cancer; 2023 Jun; 22(1):100. PubMed ID: 37365642
[TBL] [Abstract][Full Text] [Related]
3. Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression.
Mueller KP; Piscopo NJ; Forsberg MH; Saraspe LA; Das A; Russell B; Smerchansky M; Cappabianca D; Shi L; Shankar K; Sarko L; Khajanchi N; La Vonne Denne N; Ramamurthy A; Ali A; Lazzarotto CR; Tsai SQ; Capitini CM; Saha K
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36382633
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Mediated Non-Viral Site-Specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy.
Odé Z; Condori J; Peterson N; Zhou S; Krenciute G
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32604839
[TBL] [Abstract][Full Text] [Related]
5. Non-viral
Braun T; Pruene A; Darguzyte M; Vom Stein AF; Nguyen PH; Wagner DL; Kath J; Roig-Merino A; Heuser M; Riehm LL; Schneider A; Awerkiew S; Talbot SR; Bleich A; Figueiredo C; Bornhäuser M; Stripecke R
Front Immunol; 2023; 14():1086433. PubMed ID: 37033919
[TBL] [Abstract][Full Text] [Related]
6. High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR-T cell therapy.
Ding R; Chao CC; Gao Q
Methods Cell Biol; 2022; 167():1-14. PubMed ID: 35152989
[TBL] [Abstract][Full Text] [Related]
7. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
[TBL] [Abstract][Full Text] [Related]
8. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells.
Glaser V; Flugel C; Kath J; Du W; Drosdek V; Franke C; Stein M; Pruß A; Schmueck-Henneresse M; Volk HD; Reinke P; Wagner DL
Genome Biol; 2023 Apr; 24(1):89. PubMed ID: 37095570
[TBL] [Abstract][Full Text] [Related]
9. Integration of ζ-deficient CARs into the
Kath J; Franke C; Drosdek V; Du W; Glaser V; Fuster-Garcia C; Stein M; Zittel T; Schulenberg S; Porter CE; Andersch L; Künkele A; Alcaniz J; Hoffmann J; Abken H; Abou-El-Enein M; Pruß A; Suzuki M; Cathomen T; Stripecke R; Volk HD; Reinke P; Schmueck-Henneresse M; Wagner DL
bioRxiv; 2023 Nov; ():. PubMed ID: 38116030
[TBL] [Abstract][Full Text] [Related]
10. Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells.
Hale M; Lee B; Honaker Y; Leung WH; Grier AE; Jacobs HM; Sommer K; Sahni J; Jackson SW; Scharenberg AM; Astrakhan A; Rawlings DJ
Mol Ther Methods Clin Dev; 2017 Mar; 4():192-203. PubMed ID: 28345004
[TBL] [Abstract][Full Text] [Related]
11. Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells.
Kath J; Franke C; Drosdek V; Du W; Glaser V; Fuster-Garcia C; Stein M; Zittel T; Schulenberg S; Porter CE; Andersch L; Künkele A; Alcaniz J; Hoffmann J; Abken H; Abou-El-Enein M; Pruß A; Suzuki M; Cathomen T; Stripecke R; Volk HD; Reinke P; Schmueck-Henneresse M; Wagner DL
Blood; 2024 Mar; ():. PubMed ID: 38493479
[TBL] [Abstract][Full Text] [Related]
12. Metabolic priming of GD2
Cappabianca D; Pham D; Forsberg MH; Bugel M; Tommasi A; Lauer A; Vidugiriene J; Hrdlicka B; McHale A; Sodji QH; Skala MC; Capitini CM; Saha K
Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101249. PubMed ID: 38699288
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract][Full Text] [Related]
14. Automated generation of gene-edited CAR T cells at clinical scale.
Alzubi J; Lock D; Rhiel M; Schmitz S; Wild S; Mussolino C; Hildenbeutel M; Brandes C; Rositzka J; Lennartz S; Haas SA; Chmielewski KO; Schaser T; Kaiser A; Cathomen T; Cornu TI
Mol Ther Methods Clin Dev; 2021 Mar; 20():379-388. PubMed ID: 33575430
[TBL] [Abstract][Full Text] [Related]
15. Metabolic priming of GD2
Cappabianca D; Pham D; Forsberg MH; Bugel M; Tommasi A; Lauer A; Vidugiriene J; Hrdlicka B; McHale A; Sodji Q; Skala MC; Capitini CM; Saha K
bioRxiv; 2024 Mar; ():. PubMed ID: 38562720
[TBL] [Abstract][Full Text] [Related]
16. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
[TBL] [Abstract][Full Text] [Related]
17. Optimized two-step electroporation process to achieve efficient nonviral-mediated gene insertion into primary T cells.
Yang M; Tkach D; Boyne A; Kazancioglu S; Duclert A; Poirot L; Duchateau P; Juillerat A
FEBS Open Bio; 2022 Jan; 12(1):38-50. PubMed ID: 34510816
[TBL] [Abstract][Full Text] [Related]
18. Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of T
Madison BB; Patil D; Richter M; Li X; Tong M; Cranert S; Wang X; Martin R; Xi H; Tan Y; Weiss L; Marquez K; Coronella J; Shedlock DJ; Ostertag EM
Mol Ther Nucleic Acids; 2022 Sep; 29():979-995. PubMed ID: 36189080
[TBL] [Abstract][Full Text] [Related]
19. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Stenger D; Stief TA; Kaeuferle T; Willier S; Rataj F; Schober K; Vick B; Lotfi R; Wagner B; Grünewald TGP; Kobold S; Busch DH; Jeremias I; Blaeschke F; Feuchtinger T
Blood; 2020 Sep; 136(12):1407-1418. PubMed ID: 32483603
[TBL] [Abstract][Full Text] [Related]
20. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources.
Schmidts A; Marsh LC; Srivastava AA; Bouffard AA; Boroughs AC; Scarfò I; Larson RC; Bedoya F; Choi BD; Frigault MJ; Bailey SR; Leick MB; Vatsa S; Kann MC; Prew MS; Kleinstiver BP; Joung JK; Maus MV
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
